Evotec SE has been awarded a $2.5 million grant from The Gates Foundation (GF) to support the development of next-generation treatment regimens for tuberculosis (TB). This is the second grant awarded to Evotec by the GF focused on evaluating new and improved TB therapies using the company’s translational platforms. The new funding builds on an ongoing five-year partnership that has already generated standardized preclinical data used to select shorter, safer, and more effective TB drug combin...